Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Juan V Llau1 Department of Anaesthesiology and Critical Care Medicine, Hospital Clínic Universitari, València, SpainCorrespondence[email protected]

Raquel Ferrandis1 Department of Anaesthesiology and Critical Care Medicine, Hospital Clínic Universitari, València, Spain

Pilar Sierra2 Department of Anaesthesiology, Fundació Puigvert, Barcelona, Spain

Aurelio Gómez-Luque3 Department of Anaesthesiology and Critical Care Medicine, Hospital Clínico Universitario, Málaga, Spain

Figures & data

Table 1 Main platelet function test for monitoring aspirin/clopidogrel therapy

Download CSV Display Table

Table 2 Types of drug-eluting stent by composition

Download CSV Display Table

Figure 1 The 2007 update on the recommendations of the ACC/AHA/SCAI 2005–2007 last-updated guidelines on use of antiplatelet drugs in patients who undergo PCI.

Note: In parenthesis, the level of evidence is given.
Abbreviations: PCI, percutaneous coronary intervention; LD, loading dose; BMS, bare-metal stent; DES, drug-eluting stent; UA, unstable angina; NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction.

Table 3 Proposed stratification of the hemorrhagic risk related with the continuation of antiplatelet agents through the perioperative period and the thrombotic risk associated with their discontinuation

Download CSV Display Table

Table 4 Risk factors of stent thrombosis

Download CSV Display Table

Table 5 Clinical risk score for prediction of stent thrombosis and risk stratification as developed by Baran et al91

Download CSV Display Table

Figure 2 Perioperative management of antiplatelet therapy in patients with drug-eluting stents (DES).

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Table 1 Main platelet function test for monitoring aspirin/clopidogrel therapy

Table 2 Types of drug-eluting stent by composition

Table 3 Proposed stratification of the hemorrhagic risk related with the continuation of antiplatelet agents through the perioperative period and the thrombotic risk associated with their discontinuation

Table 4 Risk factors of stent thrombosis

Table 5 Clinical risk score for prediction of stent thrombosis and risk stratification as developed by Baran et al91

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Figures & data

Table 1 Main platelet function test for monitoring aspirin/clopidogrel therapy

Table 2 Types of drug-eluting stent by composition

Table 3 Proposed stratification of the hemorrhagic risk related with the continuation of antiplatelet agents through the perioperative period and the thrombotic risk associated with their discontinuation

Table 4 Risk factors of stent thrombosis

Table 5 Clinical risk score for prediction of stent thrombosis and risk stratification as developed by Baran et al91

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date